CTLA4 and cancer: Meta-analyses performed by Geng et al. (2015) [50] and Li et al. (2021) [52] found a strong positive correlation between CD8+ TILs and good outcomes in cancer patients treated with conventional checkpoint inhibitors (i.e., CTLA-4, PD1, and PDL1).